Alkermes reports positive topline Phase 3 REVITALYZ results for LUMRYZ in idiopathic hypersomnia and plans to file an sNDA with the FDA by the end of 2026.
https://finviz.com/quote?t=ALKS&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.